84 results found. Viewing page 1 of 9. Go to page 1 2  . . . 8 9   Next

    Inform Diagnostics GI Pathologists Recognized by AACC for Outstanding Research Abstract

    IRVING, Texas, July 31, 2018 — A research abstract authored by pathologists at Inform Diagnostics has been awarded “Outstanding Abstract” in the 2018 Therapeutic Drug Management and Toxicology Division Abstract Competition conducted by the American Association for Clinical Chemistry (AACC). Titled “ Therapeutic Drug Monitoring of Monoclonal Antibody in Inflammatory Bowel ...

    Continue Reading

    Inform Diagnostics GI Pathologists Will Present Four Posters at the AGA’s Digestive Disease Week

    Inform Diagnostics GI Pathologists Will Present Four Posters at the AGA’s Digestive Disease Week IRVING, Texas, May 23, 2018 — Four research posters from GI pathologists at Inform Diagnostics, formerly Miraca Life Sciences, have been accepted for the American Gastroenterological Association’s annual meeting, Digestive Disease Week. The conference will be held June 2–5 in ...

    Continue Reading

    GI Pathologists at Inform Diagnostics Publish Noteworthy Articles in Major Journals

    IRVING, Texas, May 14, 2018 — GI pathologists at Inform Diagnostics, formerly Miraca Life Sciences, continue to publish noteworthy articles in respected peer-reviewed medical journals. One recent article challenges current clinical assumptions about gastrointestinal polyps. Published in American Journal of Gastroenterology, “Lesions of All Types Exist in Colon Polyps of All ...

    Continue Reading

    Inform Diagnostics’ Previous Owner Miraca Holdings Announces Agreement in Principle with DOJ

    IRVING, Texas, May 2, 2018 — The previous owner of Inform Diagnostics, Miraca Holdings (MHD), announced today that its former subsidiary Miraca Life Sciences (now Inform Diagnostics) has reached an agreement in principle with the Department of Justice to enter into a civil settlement for $63.5 million related to an investigation that began in 2014. According to Miraca Holdings’ press ...

    Continue Reading

    Biocept and Miraca Life Sciences Enter Into Marketing Agreement to Expand Target Selector Testing in the United States

    MLS to market Biocept’s proprietary liquid biopsy testing platform in key sales territories, with potential to expand the agreement in the future SAN DIEGO (October 3, 2017) – Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that ...

    Continue Reading

    Renflexis™ Is Commercially Available from Inform Diagnostics

    IRVING, Texas, January 19, 2018 — Inform Diagnostics, formerly Inform Diagnostics Life Sciences, announced today that therapeutic drug monitoring is commercially available for Renflexis (infliximab-abda), a biosimilar of Remicade® (infliximab). Since launching the InformTx™ therapeutic drug monitoring (TDM) services in June 2016, the company has expanded its TDM testing to now ...

    Continue Reading

    Miraca Life Sciences Announces Company Name Change to Inform Diagnostics

    IRVING, Texas, January 8, 2018 — Inform Diagnostics Life Sciences announced today that it has changed its name to Inform Diagnostics effective immediately. The company was acquired in November by Avista Capital Partners from previous owner Miraca Holdings. The name Inform Diagnostics and new logo were chosen to highlight the company’s focus on providing pathology and diagnostic ...

    Continue Reading

    Avista Capital Partners Completes Acquisition of Miraca Life Sciences

    IRVING, Texas and NEW YORK, Nov. 20, 2017 — Avista Capital Partners (“Avista”), a leading private equity firm, today announced the completion of its acquisition of Inform Diagnostics Life Sciences (“MLS” or the “Company”) from Miraca Holdings Inc. Continue reading the press release at the Avista website.

    Continue Reading

    Renflexis™ is Latest Addition to Therapeutic Drug Monitoring by Miraca Life Sciences

    IRVING, Texas, October 16, 2017 — Inform Diagnostics Life Sciences, the largest U.S. independent anatomic pathology laboratory, continues to expand in clinical pathology: its InformTx™ therapeutic drug monitoring (TDM) has begun the validation process for Renflexis™ (infliximab-abda), a biosimilar of Remicade® (infliximab). Testing will be commercially available in early ...

    Continue Reading

    Biocept and Miraca Life Sciences Enter Into Marketing Agreement to Expand Target Selector Testing in the United States

    MLS to market Biocept’s proprietary liquid biopsy testing platform in key sales territories, with potential to expand the agreement in the future SAN DIEGO (October 3, 2017) – Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that ...

    Continue Reading
84 results found. Viewing page 1 of 9. Go to page 1 2  . . . 8 9   Next